E4. Tamoxifen and gynaecological side-effects: An update

European Journal of Cancer, Supplement

Volumn 2, Issue 9 SPEC. ISS., 2004, Pages 22-23

  Mourits, M J ^a   Hollema, H ^a   Willemse, P H ^a   De Vries, E G ^a   Van Der Zee, A G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

AMENORRHEA; BREAST CANCER; CONFERENCE PAPER; DRUG EFFECT; ENDOMETRIUM CANCER; HOT FLUSH; HUMAN; OLIGOMENORRHEA; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SIDE EFFECT; TERATOGENESIS; VAGINA BLEEDING;

EID: 9744245430     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2004.08.004     Document Type: Conference Paper

References (9)

1. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessement on the aromatase inhibitors as adjuvant therapy for women with hormone receptor positive breast cancer status report 2002. J Clin Oncol 2002, 20, 3317-3327.
2. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynaecologic side effects: a review. Obstet Gynecol 2001, 97, 855-858.
3. Mourits MJE, De Vries EGE, Willemse PHB, et al. Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer 1999, 79, 1761-1764.
4. Chang J, Powles TJ, Ashley SE, Iveson T, Gregory RK, Dowsett M. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat 1998, 48, 81-85.
5. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres ALERT Group. Assessment of Liver and Endometrial Cancer Risk following Tamoxifen. Lancet 2000, 356, 881-887.
6. Mourits MJ, Willemse PH, de Vries EG, van der Zee AG. Tamoxifen and endometrial screening. J Clin Oncol 2000, 18, 446-468.
7. Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive screening. Eur J Obstet Gynecol Reprod Biol 2002, 101, 58-63.
8. Mourits MJE, Van der Zee AGJ, Willemse PHB, Ten Hoor KA, Hollema H, De Vries EGE. Discrepancy between ultrasonographic and hysteroscopic and pathologic endometrial findings in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol 1999, 73, 21-26.
9. Mourits MJ, Bockermann I, de Vries EG, et al. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 2002, 86, 1546-1550.